Abstract
Background
Invasive meningococcal disease remains a public health concern because of its rapid onset and significant risk of death and long-term disability. New meningococcal serogroup B and combination serogroup ACWY vaccines are being considered for publicly funded immunization programs in many countries. Contemporary costing data associated with invasive meningococcal disease are required to inform cost-effectiveness analyses.
Objective
The objective of this study was to estimate costs and resource utilization associated with acute infection and the long-term care of invasive meningococcal disease.
Data Sources and Methods
PubMed, EMBASE, The Cochrane Library, health economic databases, and electronically available conference abstracts were searched. Studies reporting any costs associated with acute infection and long-term sequelae of invasive meningococcal disease in English were included. All costs were converted into purchasing power parity-adjusted estimates [international dollars (I$)] using the Campbell and Cochrane Economics Methods Group and the Evidence for Policy and Practice Information and Coordinating Centre cost converter.
Results
Fourteen studies met our eligibility criteria and were included. The mean costs of acute admission ranged from I$1629 to I$50,796, with an incremental cost of I$16,378. The mean length of hospital stay was reported to be 6–18 days in multiple studies. The average costs reported for readmissions ranged from I$7905 to I$15,908. Key variables such as the presence of sequelae were associated with higher hospitalization costs and longer inpatient stay. No studies estimated direct non-healthcare costs and productivity loss. Ten studies reported only unadjusted mean values without using appropriate statistical methods for adjustment.
Conclusions
Invasive meningococcal disease can result in substantial costs to healthcare systems. However, costing data on long-term follow-up and indirect costs used to populate health economic models are lacking.
Similar content being viewed by others
Data Availability Statement
The full dataset including data extracted from the full-text review and quality assessment results that support the findings of this study are available from the corresponding author upon request. The authors declare that all other data supporting the findings of this study are available within the article and its supplementary information files.
References
Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20–5.
Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774–83.
Edge C, Waight P, Ribeiro S, Borrow R, Ramsay M, Ladhani SN. Clinical diagnoses and outcomes of 4,619 hospitalised cases of laboratory-confirmed invasive meningococcal disease in England: linkage analysis of multiple national databases. J Infect. 2016;73(5):427–36.
Nadel S. Prospects for eradication of meningococcal disease. Arch Dis Child. 2012;97(11):993–8.
Wang B, Clarke M, Thomas N, Howell S, Afzali HH, Marshall H. The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children. Pediatr Infect Dis J. 2014;33(3):316–8.
Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;24(27 Suppl. 2):B51–63.
Department of Health Australian Government. Invasive meningococcal disease: national surveillance report, with a focus on MenW, December 2016 [updated 13 Oct 2017]. https://acpc.gov.au/internet/main/publishing.nsf/Content/5FEABC4B495BDEC1CA25807D001327FA/$File/IMD-Surveillance-report20161212.pdf. Accessed 31 May 2018.
Lahra MM, Enriquez RP. Australian meningococcal surveillance programme annual report, 2015. Commun Dis Intell Q Rep. 2016;40(4):E503–11.
European Centre for Disease Prevention and Control. Annual epidemiological report 2016: invasive meningococcal disease (2014 data). Stockholm: ECDC; 2016. https://ecdc.europa.eu/en/publications-data/invasive-meningococcal-disease-annual-epidemiological-report-2016-2014-data. Accessed 25 Jul 2017.
National Center for Immunization and Respiratory Diseases. Enhanced meningococcal disease surveillance report, 2015 [updated 9 June 2017]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report.pdf. Accessed 25 Jul 2017.
Pharmaceutical Benefits Advisory Committee. Multicomponent meningococcal group B vaccine, 0.5 mL, injection, prefilled syringe, Bexsero®: July 2015. Pharmaceutical Benefits Scheme; 2014. http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2015-07/mulit-component-meningococcal-group-b-vaccine-psd-july-2015. Accessed 25 Jul 2017.
Pharmaceutical Benefits Advisory Committee. Multicomponent meningococcal group B vaccine, 0.5 mL, injection, prefilled syringe, Bexsero®: July 2014. Pharmaceutical Benefits Scheme; 2014. http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2014-07/meningococcal-vaccine-psd-07-2014. Accessed 25 Jul 2017.
Pharmaceutical Benefits Advisory Committee. Multicomponent meningococcal group B vaccine, 0.5 mL, injection, prefilled syringe, Bexsero®: November 2013. Pharmaceutical Benefits Scheme; 2013. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-11/meningococcal-vaccine. Accessed 25 Jul 2017.
Joint Committee on Vaccination and Immunisation (JCVI). JCVI interim position statement on use of Bexsero® meningococcal B vaccine in the UK 2013 [updated July 2013]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224896/JCVI_interim_statement_on_meningococcal_B_vaccination_for_web.pdf. Accessed 25 Jul 2017.
Joint Committee on Vaccination and Immunisation (JCVI). JCVI position statement on use of Bexsero® meningococcal B vaccine in the UK 2014 [updated 21 March 2014]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/252859/JCVI_MenB_Update.pdf. Accessed 5 Sep 2017.
Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725.
Tu HA, Deeks SL, Morris SK, Strifler L, Crowcroft N, Jamieson FB, et al. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Vaccine. 2014;32(42):5436–46.
Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653–71.
Anonychuk A, Woo G, Vyse A, Demarteau N, Tricco AC. The cost and public health burden of invasive meningococcal disease outbreaks: a systematic review. Pharmacoeconomics. 2013;31(7):563–76.
Martinon-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2 Suppl.):S12–20.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;21(339):b2700.
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.
Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D, et al. A checklist for retrospective database studies: report of the ISPOR Task Force on Retrospective Databases. Value Health. 2003;6(2):90–7.
Kleine-Budde K, Touil E, Moock J, Bramesfeld A, Kawohl W, Rossler W. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord. 2014;16(4):337–53.
Ernstsson O, Gyllensten H, Alexanderson K, Tinghog P, Friberg E, Norlund A. Cost of illness of multiple sclerosis: a systematic review. PLoS One. 2016;11(7):e0159129.
Kim DD, Basu A. Estimating the medical care costs of obesity in the United States: systematic review, meta-analysis, and empirical analysis. Value Health. 2016;19(5):602–13.
Jarbrink K, Ni G, Sonnergren H, Schmidtchen A, Pang C, Bajpai R, et al. The humanistic and economic burden of chronic wounds: a protocol for a systematic review. Syst Rev. 2017;6(1):15.
Budhia S, Mikyas Y, Tang M, Badamgarav E. Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization. Pharmacoeconomics. 2012;30(2):147–70.
Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015;33(8):811–31.
Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial fibrillation. Value Health. 2012;15(2):240–8.
Bahia L, Toscano CM, Takemoto ML, Araujo DV. Systematic review of pneumococcal disease costs and productivity loss studies in Latin America and the Caribbean. Vaccine. 2013;2(31 Suppl. 3):C33–44.
Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6(1):51–9.
OANDA. Historical exchange rates 2018 [cited 23 April 2018]. https://www.oanda.com/fx-for-business/historical-rates. Accessed 31 May 2018.
Kontopantelis E, Reeves D. metaan: random-effects meta-analysis. Stata J. 2010;10(3):395.
StataCorp. Stata statistical software: release 14. College Station: StataCorp LP; 2015.
Clarke C, Mallonee S. State-based surveillance to determine trends in meningococcal disease. Public Health Rep. 2009;124(2):280–7.
Constenla D, Carvalho A, Alvis Guzman N. Economic impact of meningococcal outbreaks in Brazil and Colombia. Open Forum Infect Dis. 2015;2(4):ofv167.
Davis KL, Bell TJ, Miller JM, Misurski DA, Bapat B. Hospital costs, length of stay and mortality associated with childhood, adolescent and young adult meningococcal disease in the US. Appl Health Econ Health Policy. 2011;9(3):197–207.
Davis KL, Misurski D, Miller J, Karve S. Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Hum Vaccin. 2011;7(4):458–65.
Davis KL, Misurski D, Miller JM, Bell TJ, Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. Hum Vaccin. 2011;7(1):96–101.
Gil-Prieto R, Garcia-Garcia L, Alvaro-Meca A, Gonzalez-Escalada A, Viguera Ester P, Gil De Miguel A. The burden of hospitalizations for meningococcal infection in Spain (1997–2008). Vaccine. 2011;29(34):5765–70.
Hanquet GC, Agnew E, Trotter CL, Robays J, Dubois, Devriese S, et al. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study. Health technology assessment (HTA). 2014; KCE reports 231.
Karve S, Misurski D, Miller J, Davis KL. Costs of sequelae associated with invasive meningococcal disease: findings from a US managed care population. Health Outcomes Res Med. 2011;2(4):e215–26.
Letouze D, Yao G, Clarke SC. The costs associated with the public health management of a cluster of meningococcal infection in England. Vaccine. 2014;32(43):5549–51.
Montero JM, Prieto RG, Alejandre CG, Meca LA, Portugal P, de Miguel AG. Hospital admissions for meningococcal infection in Spain (1997–2005). J Infect. 2009;58(1):15–20.
O’Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: hospital case characteristics and costs by age. Value Health. 2006;9(4):236–43.
Pinzon-Redondo H, Coronell-Rodriguez W, Diaz-Martinez I, Guzman-Corena A, Constenla D, Alvis-Guzman N. Estimating costs associated with a community outbreak of meningococcal disease in a colombian Caribbean city. J Health Popul Nutr. 2014;32(3):539–48.
Tirani M, Meregaglia M, Melegaro A. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme. PLoS One. 2015;10(4):e0123383.
Wang B, Haji Ali Afzali H, Marshall H. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Vaccine. 2014;32(37):4791–8.
Benard S, Wright C, Voisine J, Olivier CW, Gaudelus J. Lifetime cost of meningococcal disease in France: scenarios of severe meningitis and septicemia with purpura fulminans. J Infect Public Health. 2016;9(3):339–47.
Darba J, Kaskens L, Hark M, Wright C. Costs of surviving meningococcal disease in Spain: evaluation for two cases of severe meningitis and septicaemia. Vaccine. 2014;32(39):5006–12.
Wright C, Wordsworth R, Glennie L. Counting the cost of meningococcal disease: scenarios of severe meningitis and septicemia. Paediatr Drugs. 2013;15(1):49–58.
Kennedy ITR, van Hoek AJ, Ribeiro S, Christensen H, Edmunds WJ, Ramsay ME, et al. Short-term changes in the health state of children with group B meningococcal disease: a prospective, national cohort study. PLoS One. 2017;12(5):e0177082.
Vyse A, Anonychuk A, Jakel A, Wieffer H, Nadel S. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11(6):597–604.
Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2 Suppl.):S3–11.
Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, et al. Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study. Clin Infect Dis. 2015;60(8):e27–35.
Christensen H, Irving T, Koch J, Trotter CL, Ultsch B, Weidemann F, et al. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero® to reduce meningococcal group B disease in Germany. Vaccine. 2016;34(29):3412–9.
Gasparini R, Landa P, Amicizia D, Icardi G, Ricciardi W, de Waure C, et al. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: a cost-effectiveness analysis. Hum Vaccin Immunother. 2016;12(8):2148–61.
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015. p. 245–50.
Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ. Meningococcal serogroup A, C, W(1)(3)(5) and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLoS One. 2013;8(5):e65036.
Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990–1994. Rev Infect Dis. 1998;26(5):1159–64.
Lecocq H, Parent du Chatelet I, Taha MK, Levy-Bruhl D, Dervaux B. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Vaccine. 2016;34(19):2240–50.
Balmer P, Burman C, Serra L, York LJ. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018. https://doi.org/10.1080/21645515.2018.1454570 (Epub ahead of print).
Breakwell L, Whaley M, Khan UI, Bandy U, Alexander-Scott N, Dupont L, et al. Meningococcal carriage among a university student population: United States, 2015. Vaccine. 2018;36(1):29–35.
McNamara LA, Thomas JD, MacNeil J, Chang HY, Day M, Fisher E, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak: Oregon, 2015–2016. J Infect Dis. 2017;216(9):1130–40.
Shaker R, Fayad D, Dbaibo G. Challenges and opportunities for meningococcal vaccination in the developing world. Hum Vaccin Immunother. 2018. https://doi.org/10.1080/21645515.2018.1434463 (Epub ahead of print).
Australian Technical Advisory Group on Immunisation. The Australian immunisation handbook. 10th ed. Canberra: Australian Government Department of Health; 2015 (2015 update).
Borrow R, Alarcon P, Carlos J, Caugant DA, Christensen H, Debbag R, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16(4):313–28.
Timmis JK, Black S, Rappuoli R. Improving accountability in vaccine decision-making. Expert Rev Vaccines. 2017;16(11):1057–66.
Committee Pharmaceutical Benefits Advisory. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 5.0). Canberra: Australian Government Department of Health and Ageing; 2016.
Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine. 2005;23(19):2470–6.
Carter D, Vogan A, Haji Ali Afzali H. Governments need better guidance to maximise value for money: the case of Australia’s Pharmaceutical Benefits Advisory Committee. Appl Health Econ Health Policy. 2016;14(4):401–7.
Mihaylova B, Briggs A, O’Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897–916.
Desmedt M, Vertriest S, Hellings J, Bergs J, Dessers E, Vankrunkelsven P, et al. Economic impact of integrated care models for patients with chronic diseases: a systematic review. Value Health. 2016;19(6):892–902.
Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327–37.
Jacobs P, Ohinmaa A, Brady B. Providing systematic guidance in pharmacoeconomic guidelines for analysing costs. Pharmacoeconomics. 2005;23(2):143–53.
Onukwugha E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Cost-of-illness studies: an updated review of current methods. Pharmacoeconomics. 2016;34(1):43–58.
Acknowledgements
Helen Marshall acknowledges support from the National Health and Medical Research Council of Australia: Career Development Fellowship (1084951).
Author information
Authors and Affiliations
Contributions
BW, HM, LG, and HA conceived and designed the study. BW conducted the database searches, extracted, analyzed, and interpreted the data, performed a quality assessment, and produced the draft of the manuscript. RS extracted data and performed a quality assessment. HM, RS, LG, and HA contributed to, reviewed, and edited the manuscript. HM acts as the overall guarantor.
Corresponding author
Ethics declarations
Conflict of interest
Helen Marshall is an independent investigator on clinical trials of investigational vaccines manufactured by pharmaceutical companies including GlaxoSmithKline, Novavax, and Pfizer. Her institution has received funding for investigator-led research from GlaxoSmithKline, Sanofi-Pasteur, Pfizer, and Novartis Vaccines. Bing Wang, Renee Santoreneos, Hossein Afzali, and Lynne Giles have no conflicts of interest directly relevant to the content of this article.
Funding
No funding was received for the preparation of this article.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Wang, B., Santoreneos, R., Afzali, H. et al. Costs of Invasive Meningococcal Disease: A Global Systematic Review. PharmacoEconomics 36, 1201–1222 (2018). https://doi.org/10.1007/s40273-018-0679-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-018-0679-5